New Jersey prescribers and pharmacists can now track patients’ use of controlled dangerous substances (“CDS”) on a new NJ PMP platform that automatically examines the data on file, analyzes it, and generates an interactive, patient-centered report with visual enhancements – including patient risk alerts – to ensure that patients are not being overprescribed opioid pain medications that can lead to addiction, overdose, and death. Grewal, the Division of Consumer Affairs, and the New Jersey Coordinator for Addiction Responses and Enforcement Strategies ('NJ CARES') today announced enhancements to the NJ Prescription Monitoring Program (“NJ PMP”) that make it easier for prescribers and pharmacists to identify and manage patients at risk for controlled substance abuse and misuse. New “NarxCare” Platform Includes Prescriber-to-Prescriber Messaging System and Other Technology to Better Coordinate Patient Care AG Grewal Announces Enhancements to NJ PMP that Automatically Analyze Patient CDS History and Identify, Flag Potential Addiction Risks
